On the afternoon of September 11, in response to investors' questions about the company's business situation on the Shenzhen Stock Exchange Interactive Easy platform, Yimedicine said that at present, Nippon Machinery's CRRT business has been completed and is being integrated and cultivated according to the plan, and will take the opportunity to inject it into the listed company in the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.